English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/150908
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies

AutorHellner, Karin; Mota, Alba; Moreno-Bueno, Gema ; Matías-Guiu, Xavier; Benítez, Javier; Ashour Ahmed, Ahmed
Palabras clavePrecancer
Fallopian tube
BRCA mutations
SOX2
Screening
Ovarian cancer
Fecha de publicación2016
EditorElsevier
CitaciónEBioMedicine 10: 137-149 (2016)
ResumenCurrent screening methods for ovarian cancer can only detect advanced disease. Earlier detection has proved difficult because the molecular precursors involved in the natural history of the disease are unknown. To identify early driver mutations in ovarian cancer cells, we used dense whole genome sequencing of micrometastases and microscopic residual disease collected at three time points over three years from a single patient during treatment for high-grade serous ovarian cancer (HGSOC). The functional and clinical significance of the identified mutations was examined using a combination of population-based whole genome sequencing, targeted deep sequencing, multi-center analysis of protein expression, loss of function experiments in an in-vivo reporter assay and mammalian models, and gain of function experiments in primary cultured fallopian tube epithelial (FTE) cells. We identified frequent mutations involving a 40kb distal repressor region for the key stem cell differentiation gene SOX2. In the apparently normal FTE, the region was also mutated. This was associated with a profound increase in SOX2 expression (p<2(-16)), which was not found in patients without cancer (n=108). Importantly, we show that SOX2 overexpression in FTE is nearly ubiquitous in patients with HGSOCs (n=100), and common in BRCA1-BRCA2 mutation carriers (n=71) who underwent prophylactic salpingo-oophorectomy. We propose that the finding of SOX2 overexpression in FTE could be exploited to develop biomarkers for detecting disease at a premalignant stage, which would reduce mortality from this devastating disease.
DescripciónOpen Access funded by Medical Research Council. Under a Creative Commons license.-- et al.
Versión del editorhttps://doi.org/10.1016/j.ebiom.2016.06.048
URIhttp://hdl.handle.net/10261/150908
DOI10.1016/j.ebiom.2016.06.048
Identificadoresdoi: 10.1016/j.ebiom.2016.06.048
e-issn: 2352-3964
Aparece en las colecciones: (IIBM) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
PremalignantSOX2.pdf1,56 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.